Lipids and compositions for the delivery of therapeutics

Patent metadata

Field	Value
Publication number	US-9764036-B2
Application number	US-201514953677-A
Country	US
Kind code	B2
Filing date	Nov 30, 2015
Priority date	Nov 10, 2008
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures:

First claim

We claim:

1. A lipid having the structure of formula XXXV

or a salt or isomer thereof, wherein:
R 1 and R 2 are each independently for each occurrence substituted C 10 -C 30 alkyl, optionally substituted C 10 -C 30 alkoxy, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkenyloxy, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 alkynyloxy, or optionally substituted C 10 -C 30 acyl, or linker-ligand;
R 3 is independently for each occurrence H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted alkylheterocycle, optionally substituted heterocyclealkyl, optionally substituted alkylphosphate, optionally substituted phosphoalkyl, optionally substituted alkylphosphorothioate, optionally substituted phosphorothioalkyl, optionally substituted alkylphosphorodithioate, optionally substituted phosphorodithioalkyl, optionally substituted alkylphosphonate, optionally substituted phosphonoalkyl, optionally substituted amino, optionally substituted alkylamino, optionally substituted di(alkyl)amino, optionally substituted aminoalkyl, optionally substituted alkylaminoalkyl, optionally substituted di(alkyl)aminoalkyl, optionally substituted hydroxyalkyl, optionally substituted polyethylene glycol (PEG), optionally substituted mPEG, optionally substituted heteroaryl, or optionally substituted heterocycle, or linker-ligand; or,
each R 3 taken together with the atom to which they are attached are a 3-8 membered optionally substituted cycloalkyl group or a 3-8 membered optionally substituted heterocycle group;
X and Y are each independently —O—, —S—, —N(Q)-, —C(O)—, —O(CO)—, —OC(O)N(Q)-, —N(Q)C(O)O—, —C(O)O, —OC(O)O—, —OS(O)(Q 2 )O—, or —OP(O)(Q 2 )O—;
Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, or ω-thiophosphoalkyl;
Q 1 is independently for each occurrence O or S; and,
Q 2 is independently for each occurrence O, S, N(Q)(Q), alkyl or alkoxy.

2. A lipid, or a salt or isomer thereof, selected from the group consisting of:

3. A lipid particle comprising a lipid of claim 1 .

4. The lipid particle of claim 3 , wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

5. The lipid particle of claim 4 , wherein the lipid particle consists essentially of
a. a lipid of claim 3 ;
b. a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM;
c. a sterol; and
d. PEG-DMG,
in a molar ratio of about 20-60% lipid of claim 1 :5-25% neutral lipid:25-55% sterol:0.5-15% PEG-DMG.

6. The lipid particle of claim 3 , further comprising a therapeutic agent.

7. The lipid particle of claim 6 , wherein the therapeutic agent is a nucleic acid.

8. The lipid particle of claim 7 , wherein the nucleic acid is a plasmid.

9. The lipid particle of claim 7 , wherein the nucleic acid is an immunostimulatory oligonucleotide.

10. The lipid particle of claim 7 , wherein the nucleic acid is selected from the group consisting of an siRNA, an antisense oligonucleotide, a microRNA, an antagomir, an aptamer, and a ribozyme.

11. The lipid particle of claim 10 , wherein the nucleic acid is an siRNA.

12. A pharmaceutical composition comprising a lipid particle of claim 6 and a pharmaceutically acceptable excipient, carrier, or diluent.

13. A method of modulating the expression of a target gene in a cell, comprising providing to a cell the lipid particle of claim 6 .

14. The method of claim 13 , wherein the therapeutic agent is selected from an siRNA, an antagomir, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a ribozyme, an aptamer or an antisense oligonucleotide.

15. A method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 12 , wherein the therapeutic agent is selected from an siRNA, a microRNA, an antisense oligonucleotide, and a plasmid capable of expressing an siRNA, a microRNA, or an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof.

16. A method of treating a disease or disorder characterized by underexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 12 , wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof.

17. A method of inducing an immune response in a subject, comprising providing to the subject the pharmaceutical composition of claim 12 , wherein the therapeutic agent is an immunostimulatory oligonucleotide.

18. The lipid of claim 1 , wherein the PEG has a molecular weight range from 100 to 40,000.

19. The lipid of claim 1 , wherein the mPEG has a molecular weight range from 120 to 40,000.

20. The lipid of claim 1 , wherein R 1 and R 2 are each independently C 10 -C 30 alkenyl.

21. The lipid of claim 1 , wherein X and Y are each independently —O—.

22. A lipid particle comprising a lipid of claim 2 .

Assignees

• Arbutus Biopharma Corp

Inventors

• Manoharan Muthiah
• Rajeev Kallanthottathil G
• Butler David
• Nair Jayaprakash K
• Jayaraman Muthusamy
• Eltepu Laxman

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K9/5123

  Organic compounds, e.g. fats, sugars · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title